Skip to main content
    A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $28.49
    +0.62 (+2.22%)

    Market Cap: $4.70B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Adaptive Biotechnologies Corp (ADPT) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Adaptive Biotechnologies (ADPT) trades at 15.3x sales and 25.9x book value. Its P/S of 15.3x is above its 5-year median of 7.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales15.3x
    Price to book25.9x
    PEGN/A
    FCF yield-0.2%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S15.3x7.0xN/A
    P/B25.9x3.3xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 7 year ends shown, its P/S ranged from 4.2x in 2023 to 81.5x in 2020.

    Year endPriceP/SP/B
    2025$16.248.9x11.4x
    2024$6.004.9x4.4x
    2023$4.904.2x2.3x
    2022$7.645.9x2.4x
    2021$28.0625.5x6.6x
    2020$59.1381.5x10.9x
    2019$29.9221.7x6.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About ADPT

    What is ADPT's price to sales ratio?

    Adaptive Biotechnologies has a price to sales ratio of 15.3x.